SCHEMBL1359909

SCHEMBL1359909

CC(C)(C)c1cc(-c2ccc[nH]c2=O)cc2c(C(=O)N3CCC(NS(C)(=O)=O)CC3)coc12

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.39
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
SFRP1 Q8N474 3/20 0.32
TDO2 P48775 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
BRD4 O60885 2/20 0.30
TRPV4 Q9HBA0 1/20 0.30
RORC P51449 1/20 0.30
NR1I2 O75469 1/20 0.30
CACNA1B Q00975 1/20 0.30
APOB P04114 1/20 0.30
MTTP P55157 1/20 0.30
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30
CCR8 P51685 1/20 0.30
OPRM1 P35372 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1358332 0.91 CYP3A4 (0.37) CYP3A4KMT2ABRD4
SCHEMBL1358334 0.91 CYP3A4 (0.37) CYP3A4KMT2ABRD4
SCHEMBL1359903 0.91 CYP3A4 (0.37) CYP3A4KMT2ABRD4
SCHEMBL1357846 0.88 HSP90AA1 (0.40) CYP3A4HSP90AA1HSP90AB1
SCHEMBL1360205 0.87 KDM1A (0.38) CYP3A4HSP90AA1HSP90AB1
SCHEMBL1359886 0.87 EPHX2 (0.34) CYP3A4MEN1KMT2A
SCHEMBL1360761 0.86 PARP1 (0.40) CYP3A4BRD4
SCHEMBL1359911 0.86 MAPT (0.34) CYP3A4CNR2MEN1KMT2A
SCHEMBL1359385 0.86 MAPT (0.36) CYP3A4MEN1KMT2ABRD4
SCHEMBL1358011 0.86 CYP3A4 (0.37) CYP3A4BRD4RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US claimed
EP-2334662-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. Hoffmann-La Roche AG (CH) 2011-06-22 EP claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS CYP3A4 713/4885CNR1 738/4885CNR2 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.